ABSTRACT Oral and oropharyngeal cancer remains a major global public health burden, but the literature addressing this disease is still organized predominantly around who develops it rather than around what determines life after diagnosis. That imbalance is consequential because diagnosis initiates a new scientific problem. Once oral or oropharyngeal cancer is established, the clinically relevant questions expand beyond incidence to include overall and disease‐specific survival, recurrence, progression, treatment completion, treatment tolerance, swallowing, speech, nutrition, oral function, quality of life, and inequities in care delivery. This review argues that these postdiagnosis questions are best organized within survival epidemiology, a field of medical science dedicated to the study of health outcomes after diagnosis in populations living with an established disease. In this framing, survival epidemiology is not merely survival analysis, survivorship research, clinical epidemiology, or a comparison between prediagnosis disease prevention and postdiagnosis disease survival. It is a postdiagnosis population science that integrates epidemiology, oncology, dentistry, rehabilitation, public health, molecular medicine, and causal inference around the realities created by diagnosis. Oral and oropharyngeal cancer provides a strong model for this field because diagnosis changes the dominant time scale, available interventions, relevant confounders, and bias structure. Tobacco and alcohol remain central etiologic exposures, but postdiagnosis questions focus on cessation, persistence, dose change, recurrence, second primary tumors, and treatment interaction rather than on first cancer occurrence alone. HPV vaccination is a prevention intervention, whereas HPV or p16 status after diagnosis influences prognosis, staging, treatment selection, deintensification debates, and survivorship trajectories. Oral hygiene, dental care, nutritional status, swallowing function, treatment delay, molecular signatures, and care integration are similarly transformed from background correlates into potential postdiagnosis determinants of clinical outcome. We propose a disease‐specific survival epidemiology agenda for oral and oropharyngeal cancer that prioritizes explicit time zero at diagnosis or treatment decision points, target‐trial emulation, careful distinction between prediction and causal effect, attention to collider stratification and immortal time bias, time‐varying exposure assessment, competing‐risk and multistate models, longitudinal biomarker and functional measurement, and systematic capture of dental, nutritional, rehabilitation, molecular, and patient‐reported data. Risk‐survival nonequivalence, known more broadly as Cuomo's paradox, is treated as one testable manifestation of this field rather than as the field itself. Public health practice should accordingly shift from a single prevention‐centered framework toward a dual‐track model that both prevents new cancers and improves outcomes for people already living with these malignancies. In oral and oropharyngeal cancer, raising awareness of survival epidemiology is, therefore, not a semantic exercise; it is a practical step toward better evidence, clearer guidance, and longer and better lives after diagnosis.
Raphael Cuomo (Fri,) studied this question.